TScan Therapeutics, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K filed 2026-09-30 reports Item 5.02 disclosure regarding departure of director(s) or officer(s) and changes to compensatory arrangements, effective 2026-09-24. Specific names, titles, amounts, equity awards, and severance terms are not provided in the accessible filing metadata; full details require review of the complete 8-K document text.
Why this rating
Officer/director changes are routine corporate governance disclosures. Without named individuals, quantified severance, or equity values stated, impact cannot be assessed; no material transaction amount specified.
Extracted items
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.